In this paper, we address methods of multivariate regression. We discuss the value of regression compared to matched pairs analysis, methods of coding variables, basic concepts of the Cox model and interpretation of results of the Cox model. We present methods of handling variables whose effect changes with time. We present methods to check the assumptions of the Cox regression. Finally, and perhaps most importantly, we provide suggestions for presenting the results in clear and thorough tables and graphs. Bone Marrow Transplantation (2001) 28, 1001-1011. Keywords: Cox model; proportional hazards models; fixed and time-dependent covariate In the first paper in this series, 1 we presented important considerations in basic statistics and univariate analyses for studies involving outcomes of bone marrow transplantation. Regression or multivariate analysis is commonly used in studying the outcomes of bone marrow transplantation. Regression models are used in two distinct situations. First, they are used in prognostic factor studies. These are studies designed to determine patient, donor, disease and treatment characteristics, which influence some outcome of the therapy. They typically use stepwise regression techniques to build a model that can be used to predict the outcome of a patient based on a series of factors measured at the time of transplantation.
In the first paper in this series, 1 we presented important considerations in basic statistics and univariate analyses for studies involving outcomes of bone marrow transplantation. Regression or multivariate analysis is commonly used in studying the outcomes of bone marrow transplantation. Regression models are used in two distinct situations. First, they are used in prognostic factor studies. These are studies designed to determine patient, donor, disease and treatment characteristics, which influence some outcome of the therapy. They typically use stepwise regression techniques to build a model that can be used to predict the outcome of a patient based on a series of factors measured at the time of transplantation.
Second, regression models are frequently used to make adjustments for imbalances in prognostic factors between groups of patients and therefore are an excellent method to make planned comparisons between treatments. Interaction terms can be added to the models to allow for subgroup analysis.
An alternative to use of regression models for making treatment comparisons is the use of matched pairs analysis. Here, each case given a particular treatment is matched on some patient-or disease-specific characteristic such as age, sex, primary disease state, etc to a control patient. ). In most clinical applications we prefer a regression-adjusted test of treatments to a matched pairs analysis for several reasons. First, the regression analysis allows us to use all the patient information, including those patients for whom we cannot find a match. Second, in the matched pairs analysis only those pairs where the smaller of the pair's on-study time corresponds to a death are used in the analysis so the effective sample size is less than that of the corresponding regression analysis. Third, the regression analysis allows us to look for differential effects of treatments in some subgroups of patients. This is not possible with a matched pairs analysis. Fourth, any factor for which the patients are matched cannot be analyzed, nor can its effect on outcome be quantified. Fifth, a frequent misconception is that increasing the size of the matched cohort leads to greater statistical power. In practice, however, little is gained beyond a two or three to one matching. 3 Finally, the matched pairs analysis, which must involve prospective matching, is administratively harder to implement.
Regression models can be applied to most outcomes of a BMT. Most commonly regression models are used for time to event data. Time to event data includes data where we have an on-study time and an event indicator. Examples are data on survival, relapse, death in remission, and disease-free survival. Here regression models typically focus on modelling the rate at which these events occur over time.
The most common regression model is the Cox 4 proportional hazards model, which models the timing of events through the hazard rate (see the appendix for definitions of statistical terms). Another possible model for this type of data is the class of accelerated failure time models 5 (AFT), which models the relationship between risk factors and outcome through the logarithm of the event time. The AFT models are parametric models that require a very specific model for the baseline survival function and are rarely used in BMT studies for this reason. Studies have shown that when the incorrect model is assumed for the baseline survival rate the AFT may lead to misleading results. 6 In the following sections we will explain how to interpret the results of a Cox regression model for BMT data. We will illustrate how to check whether this model is an appropriate one and suggest some ways the model can be improved.
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We will point out common mistakes made in applying and interpreting this model.
Coding risk factors
BMT studies involve a number of different types of covariates. These covariates or risk factors may be: (1) continuous measures of patient status, such as age, pre-transplant white blood cell count (WBC), time from diagnosis to transplant, etc; (2) binary, such as sex; or (3) categorical such as race (white, black, other) or stem cell source (marrow, blood, both). Each of the regression models we consider has a different interpretation of these three types of risk factor, but some common principles do hold.
First, continuous covariates, such as age or WBC, are characteristics which we can, in theory measure, with a degree of accuracy. A common mistake is to code ordinal categorical variables as continuous covariates. For example, year of transplant or stage of disease are ordered categorical variables which should not be treated as continuous covariates. When one incorrectly treats these ordered categorical variables as continuous, the tests from the regression models are valid tests of trend but the risk estimates are meaningless.
Categorical variables require special care. For a risk factor with k categories we must select one category as a baseline and code the remaining (k − 1) categories as binary (0 or 1) indicators of being in each category. Selection of the baseline category is arbitrary, but it is important to realize that statistical packages will only routinely supply tests of the effect of being in one of the other categories relative to the chosen baseline category. A good analysis will report an overall P value for a categorical risk factor from a socalled multiple degree of freedom test. This P value is a test of the hypothesis that all the responses are equal against the alternative that the response in at least one category is different from the others. This test, which should always be reported, is not affected by the choice of the baseline category.
In BMT studies we can classify risk factors as fixed time or time-dependent covariates. Fixed time risk factors are those whose value is known and fixed at the start of the study. Time-dependent covariates are those whose value may change after the patients have entered the study. Examples of time varying risk factors, when the starting point is at transplant, are the most current neutrophil or WBC count (both continuous), or time varying binary variable indicating whether acute GVHD has occurred by a given time or whether the patient is still hospitalized at time t. A very common mistake made when reporting results of BMT studies is to treat time-dependent covariates as if they were fixed covariates, for example, treating occurrence of acute GVHD at some time as if it were known at the time of transplant. This leads to very misleading results. We will discuss the interpretation of time-dependent covariates later.
Missing values complicate analysis of transplant studies. Although every effort should be made to collect complete information on each covariate, this is sometimes impossible. Several approaches to models with missing data are suggested in the literature. These include imputation of missing values by using averages of covariate values for similar patients, 7 discarding any case with a missing value, or coding 'missing' as a separate category for the risk factor. We prefer the latter two methods. When there are relatively few missing values we tend to discard the patients with missing values from the data set (this is the so-called 'complete case analysis'). When we do this we like to compare the outcome between those with and without missing values to ensure we are not biasing the study by this method. When a variable has a high frequency of missing values (Ͼ10% of sample), we code an indicator variable that this risk factor is missing and include this as one of the categories when testing for this factor. This allows us to keep as much data as possible for analysis and to test if those with missing values are different from the average patient with complete data.
The Cox proportional hazards model
The most commonly used regression model for lifetime data is the Cox 4 proportional hazards regression model. This is a model for a patient's hazard rate. The hazard rate is the chance of the event of interest occurring in the next instant of time for a patient yet to experience the event. If, for example, the event is treatment failure (ie death or relapse) then the hazard rate for treatment failure at time t, h(t), is the chance of relapse or death tomorrow if the patient is alive and disease-free today (t).
The Cox model assumes that the hazard rate for a given patient can be factored into a baseline hazard rate (common to all patients) and a parametric function of the covariates which describes the patients characteristics. Thus we can express the hazard rate for patient i as
Here h 0 (t) is a baseline hazard rate that we estimate nonparametrically; Z i , is the ith patient's covariate and ␤ is the risk or regression coefficient. This is called a semiparametric model since we model the covariate effects with a parametric model, but we model the baseline hazard rate, h 0 (t), nonparametrically. Figure 1 illustrates the relationship between hazard rates for a single binary covariate based on the Cox model. Here the top curve representing a patient with the characteristic is twice the bottom curve which is for a baseline patient. The relative risk is e ␤Z = 2. Both curves are hump-shaped which is the typical shape of a hazard rate for treatment failure after transplant. This represents an increasing risk of death due to infection or GVHD early which tapers after some period of time.
Since the Cox model is based on the hazard rate when the event of interest is survival or treatment failure (see our discussion of competing risks in part 1 of this series 1 ), the model suggests a relationship between the survival functions for patients with different risk factors. The survival function for a patient with a covariate Z is equal to S o (t) exp{␤Z} . Here S o (t) is the survival function for the baseline patient. Figure 2 shows the baseline and adjusted survival curves corresponding to the Cox models in Figure 1 .
Interpretation of covariates
As stated above, in the Cox proportional hazards model the covariates act as factors multiplying the hazard rate, which is the probability of experiencing the event in question (eg death or relapse) during the next little interval (eg tomorrow). To illustrate the interpretation of covariates in the model we are using data from an IBMTR study of alternative BMT donors for leukemia. 8 The data considered consists of patients transplanted for chronic or acute leukemia with either an HLA-identical sibling donor (n = 1224), a one (n = 238) or two (n = 102) HLA antigen mismatched related donor, an HLA matched unrelated donor (n = 380) or a one-HLA antigen mismatched unrelated donor (n = 108).
Consider first the inference for a continuous covariate AGE (age of patient at transplantation in years) for the event of treatment failure ( Table 1 ). The interpretation of the estimate 0.003842 is best obtained through the risk ratio obtained using the exponential function as exp{0.003842} = 1.003849, which says that the hazard increases by a factor of 1.0038 for each year that the age of the patient increases. The standard error of 0.00237 is a bit high for the estimate to be considered statistically significant; for one parameter significance at the 5% level corresponds to the estimate being further away from zero than 1.96 standard errors. This is also reflected in the quoted P value of 0.1055 or 10.55%. Comparing two patients with an age difference of 20 years yields an increase of exp{20 × (0.003842)} = exp{0.07684} = 1.07987 = (1.003849) 20 so that a patient 20 years older has a hazard about 1.08 times higher, ie 8% higher, than the younger patient.
Another way of scoring the age effect would be to select a threshold age (such as 40 years) such that AGE40 = 0 if AGE р 40, AGE40 = 1 if AGE Ͼ 40. This dichotomization of the age effect postulates that most of the effect of age on relapse or death can be captured as a marked increase in hazard at age 40. The estimate of AGE40 is 0.163338 with standard error 0.07070, P = 0.0209 and risk ratio 1.177. So according to this, patients older than 40 have a 17.7% higher hazard of death or relapse than patients under age 40.
The choice of cutpoint between high and low risk (in the above case 40 years of age) is sometimes difficult and there is no hard and fast rule as to the choice. The best choice is one based on the existing scientific evidence from previous papers or based on clinical observation. Another possibility is to use the median in the data as a cut point. One common data-dependent approach when the cutpoint is not given at the outset is to try several cutpoints in order to locate that point with clearest significance. This however invalidates the interpretation of the hypothesis tests using the standard P values. Recent statistical research [9] [10] [11] has shown that the P values computed from this search procedure are too small and lead to false significances in most cases. There are various [12] [13] [14] (much more elaborate) statistical procedures that correct these P values so that the overall inference level is correct.
When studying a categorical variable with more than two categories it is necessary to use several 'dummy' variables. Consider for example, the patient's disease at the time of transplant, AML, ALL or CML. This factor can be coded using
The relative risk estimates of ALL will measure how much the hazard of ALL is changed relative to the baseline, which here is AML. It is best to choose a baseline category that is useful for such comparisons, and at the same time has sufficient patients (because if it contains few patients the resulting estimates will all inherit the resulting uncertainty). Note that most statistical software will choose the reference category unless specifically prompted, which will not take the above considerations into account. Table 2 shows the typical computer output for the disease factors. The interpretation is that ALL patients have a hazard of relapse or death of 1.202 times that of AML patients, and this is statistically significant with P = 0.0256. On the other hand the slightly decreased (by a factor of 0.980) hazard of CML patients relative to AML patients cannot be considered statistically significant (P = 0.77). If the relative risk of CML in relation to ALL is considered, direct calculation yields that this is 0.980/1.202 = 0.815. However, calculation of standard errors and P values requires additional information and is most easily done in practice by recoding so that ALL is the reference category and running the program once more.
When two factors are included in a model a typical output is as in Table 3 . Here the interpretation of the risk ratio of 1.240 for ALL is that an ALL patient is failing treatment at a rate 1.24 times greater than an AML patient of a similar age. Note that the relative risk is now 1.240 as compared to 1.202 in Table 2 reflecting that we have made an adjustment for age. The risk ratio of 1.240 is the same regardless of the age of the patients being compared. This model is said to have no interaction between age and disease.
In some cases we may be interested in determining if there is an interaction between two factors in their effect on outcome. To detect that, we include in the model terms involving cross products of the indicators for each factor. Table 4 illustrates this for the disease and age factors. Here we see that there is in fact an interaction between age and CML such that older CML patients have a different relationship to older AML patients than younger CML patients to younger AML patients. The relative risk of 1.037 for CML is the relative risk of treatment failure for a CML patient as compared to an AML patient when both are under 40 years of age (ie when AGE40 = 0). For patients over age 40 the relative risk of a CML patient to an AML patient is exp{0.03662 + (−0.32161)} = 0.752. Similarly, ALL patients are failing at a rate 1.254 times that of an AML patient under age 40 and at a rate exp{0.22639 + 0.21595} = 1.556 faster than that of an AML patient over age 40. To test if these relative risks are significant requires additional information not given in Table 4 . This information can be obtained by using an alternative coding of the variables. When this is done we find that for patients over age 40 the risk of treatment failure for a CML patient as compared to an AML patient of 0.752 is significantly different from 1 (P = 0.0379). This tells us that older CML patients do better then older AML patients, but for younger patients there is no difference in treatment failure rates.
Time-varying effects and time-dependent covariates
Most of the variables discussed so far are known at the time of transplantation (age, sex, WBC count, Karnofsky score, basic disease); these are called fixed or time-fixed covariates. In contrast to these stand time-dependent covariates, of which the most important in the present context is whether or not various events have happened: engraftment, platelet recovery, (first occurrence of) acute graft-versushost disease, similar for chronic GVHD. One of the important features of the Cox regression model is that it allows for inclusion of time-dependent covariates with little extra technical effort. However there are various issues of interpretation that require attention.
First, as already mentioned, time-dependent covariates are often misinterpreted as time-fixed covariates. It is incorrect to compare patients with aGVHD to patients without, as if it were known at transplantation whether or not the patients will get aGVHD. To do so would bias the estimate of the effect of aGVHD by assuming that every patient who receives a transplant is at risk of developing aGVHD, while in fact some patients die before they could experience aGVHD.
Second, sometimes the effect of some fixed covariate (eg donor age, sex) on outcome is mediated through timedependent covariates (eg GVHD). It may then confuse the assessment of the time-fixed covariates if the time-dependent covariate is also included in the analysis. This is similar to the well-established practice in epidemiology of not including intermediate variables in the analysis.
In our example we can examine the effect of acute and chronic GVHD on treatment failure. Here we code two time-dependent covariates which are the indicators that a patient has developed either acute or chronic GVHD prior to time t. Notice that the GVHD covariate is initially zero and changes to a value of one at the time GVHD is diagnosed for the patient. Fitting these models, we have Table  5 . These results tell us that a patient's risk of treatment failure increases by 1.975 when they develop acute GVHD. There is no effect on outcome due to chronic GVHD. Note that if we incorrectly coded acute and chronic GVHD as if the occurrence were known at the time of transplant (ie as fixed covariates) then we have the results in Table 6 where it appears that chronic GVHD has a highly significant benefit to the patient. This apparent benefit is entirely due to the fact that patients need to live to at least 100 days or more to develop chronic GVHD. When modelled correctly this 'benefit' is not observed.
It is important to distinguish time-dependent covariates from time-varying fixed effects. Times varying fixed effects occur when the effects of a fixed covariate on outcome change over time. To illustrate these types of effects consider the IBMTR study 15 comparing the survival of 548 HLA-identical sibling transplant patients to 196 patients treated for CML with hydroxyurea (n = 121) or interferon (n = 75). In this study time is measured from the date of diagnosis. The effect of therapy (BMT vs chemo) changed over time. Table 7 shows the estimates of the effect of BMT in three distinct time intervals. Here we see that in the first 18 months after diagnosis that BMT patients are dying at a rate 5.8 times that of patients on chemotherapy. Among those patients who survive at least 18 months there is little Table 7 Estimates of treatment effect 
Checking the model
The results of the Cox model are only valid as long as the assumptions of the model are correct. The most important is the proportionality of hazards assumption that the effects of the risk factors are constant over the follow-up time period. We need to check the proportionality assumption when fitting a Cox model. Various approaches and methods for checking the proportional hazard rate have been proposed and studied (see in Klein and Moeschberger, 2 chapter 11). We consider two commonly used approaches. One method is to add a time-dependent covariate. Suppose we need to examine the proportionality assumption for a fixed covariate Z 1 . We add a time-dependent covariate Z 2 = Z 1 ϫ log(t) to the model. If the proportionality assumption holds for Z 1 , then the regression coefficient for Z 2 should be zero, suggesting no change in Z 1 's effect on outcome over time.
As an example, in our study of alternative donors consider the factor Karnofsky score at transplant and its effect on treatment failure. Here, we dichotomize patients into good (у90%) and poor Karnofsky status. Table 8 shows the results of fitting the covariate Karn = {1 if good Karnofsky, 0 if poor} and the time-dependent covariate Karn × log(t). Here the risk ratio of 0.435 is quite meaningless. Our artificial covariate Karn ϫ log(t) is highly significant suggesting the effect of Karnofsky score changes over time.
Another approach to checking the proportionality assumption is a graphical method. To check the proportionality assumption for a discrete covariate Z 1 , after adjusting for other covariates, we fit a Cox model to other covariates stratified on Z 1 . When a Cox model is stratified on a covariate then different baseline rates are used for each level of the covariate. If the proportionality assumption holds for Z 1 , the difference in the log cumulative hazard function over any two levels of Z 1 should be constant over the follow-up time period. Alternatively, Andersen 16 proposed plotting the cumulative baseline hazard functions for each pair of levels against every other level of Z 1 . Andersen's plots should be straight lines if the proportionality assumption holds. When the proportionality assumption does not hold, these plots also summarize how the hazard rate changes over time. To illustrate these techniques we again consider the indicator of good Karnofsky score. We fit a stratified Cox model with risk factor donor type stratified on Karnofsky score. Figure 3 plots the difference in log cumulative baseline hazard (good-poor Karnofsky) which indicates that the difference is not constant. Figure 4 is the Andersen plot of cumulative baseline hazard function of good against poor Karnofsky. If proportional hazards holds this plot should be the 45°line. These plots confirm that the proportionality assumption is not valid for the risk factor of Karnofsky score.
In the situation where the proportionality assumption is clearly untenable it may sometimes be possible to partition the effects along the time axis as shown in earlier in the context of comparison of BMT with chemotherapy for CML. months, 18-56 months, more than 56 months) the proportionality assumption still holds. A similar procedure could be used for the Karnofsky score, one possibility being to distinguish between an early and a late effect according to some cutpoint t 0 . Often this cutpoint needs to be chosen from the data. Applying this procedure to this data we find a 'best' cutpoint of 2 months. For this model we see there is a benefit of having good Karnofsky for the first 2 months after transplant (RR = 0.382, P Ͻ 0.0001). In 2-month survivors, there is still a beneficial effect of good Karnofsky at transplant (P Ͻ 0.0001), but this effect is now cut in half with a relative risk of 0.644. The P values from this procedure are suspect, however, since the procedure is 'rigged' to find significance by selecting the cut point that gives us the biggest values of test statistics. Unless these P values are very small, as in this example, we need to be extremely careful in our interpretation of significance.
In some situations the non-proportionality regards a covariate for which no direct effect measure is needed. It is then often useful to relax the model assumption allowing separate underlying hazards for each level of that covariate. This is called the stratified Cox model, and often it is acceptable to assume that the rest of the covariates act multiplicatively on these hazards, with common value regardless of the level of the critical covariate. The Karnofsky score may once again provide an example. Assume that we allow separate baseline hazards for Karnofsky у90 and Ͻ90, then the effect of older age has a relative risk of 1.159 (P = 0.0378), while for an unstratified model the relative risk is 1.170 (P = 0.0270).
Presentation of results
In the previous sections we have presented a number of tables which are helpful in understanding how to interpret the Cox regression analysis. In this section, we discuss our views on how one should present these results for publication. In all but the simplest studies this presentation should involve a table of risk ratios with the appropriate confidence intervals and P values and a set of summary figures. Depending on the results of the Cox analysis the summary figures should reflect the average survival or disease-free survival for a patient with a particular risk factor, the average being over all other risk factors in the model. The curves are either the actual estimated survival curves themselves, or, when the effect being studied has nonproportional hazards, a difference between survival curves. One needs to be careful that the curves are appropriate for the outcome measure (see our discussion of competing risks in part 1 1 ). While the Cox model is valid for studying the rate of occurrence of competing risks such as relapse or death in remission, the survival curves suggested in the sequel apply only to events like survival or treatment failure. We first illustrate this on the data on unrelated donors. Table 9 shows the output of the final Cox model on which our presentation table and figures are based. This model has an indicator for each type of donor with HLA-identical siblings as the baseline, an indicator of transplantation with advanced disease (Ͼfirst chronic phase for CML; Ͼ1st remission for AML or ALL), and age Ͼ40. There is also an interaction term between donor type and disease stage. All models are stratified on good or poor Karnofsky score.
While this table is very useful in understanding the basic model, it is not the type of table we recommend for publication. This is found in Table 10 . Here we present for each Table 10 Suggested publication form of a summary Bone Marrow Transplantation factor a test of its significance. This tests the null hypotheses that all levels of the factor have the same effect on survival against the hypothesis that one of the levels of the factor is different from any other. Here the P value (a) is from such a test and it is an overall P value of the hypothesis that at least one of the donor types has a different treatment failure rate than the others, here for early disease patients. This P value, based on a so-called multiple degree of freedom test, is compared to 0.05 to judge significance or 0.01 to judge strong significance. Having determined that the factor (here donor type) is significant we then look at the pairwise comparisons of levels of the factor to determine which donor types are different from each other. We are making 5 ϫ 4/2 = 10 such pairwise comparisons, four of which are listed in the body of the table and six in the Months since transplant Adjusted probability of disease-free survival HLA-identical sibling HLA-matched unrelated One-mismatched unrelated One-mismatched related Two-mismatched related Figure 5 Adjusted probability of disease-free survival for early disease.
footnote. To ensure that we are not drawing any false conclusions we should compare each of these comparisons to 0.05/10 = 0.005 for significance (or 0.01/10 = 0.001 for strong significance). Here we see that all the alternative donors differ from HLA-identical siblings for early disease patients, but none of the alternative donors are different. Note for advanced disease using the 0.005 adjusted level we find that only two-antigen mismatched related donors are different from HLA-identical sibling donors.
The table also provides for each variable in the column the estimated relative risk as compared to the baseline category which is also given in the table and a 95% confidence interval for the relative risk. Here, for example, the value (b) tell us that, for early disease, a patient given a oneantigen mismatched related donor transplant fails the treatment at a rate 2.49 times that of an HLA-identical sibling transplant. We are 95% confident that this estimated relative risk could be as low as 1.90 or as high as 3.26. These values in many cases come directly from the regression Table 11 Suggested publication form of a summary Figure 6 Adjusted probability of disease-free survival for advanced disease.
table (Table 9 ) with the confidence intervals being computed as exp{parameter estimate Ϯ 1.96 ϫ standard error}.
Having presented the results of the study, accompanying figures are needed to summarize the main results. Here, since the relationship between donor types does not change over time an adjusted survival curve for each of the main effects is of interest. This adjusted survival curve is constructed by estimating a survival curve for each patient based on the final Cox model and then averaging these curves over patients with a similar donor type. The curve is then representative of an average patient with the condition. Figures 5 and 6 show these curves for different donor types by diseases stage.
For our second example comparing BMT to chemotherapy patients in CML, the proportional hazards model did not hold for the main effect of type of therapy. After modelling outcome we found that different risks of death for the two donor types were found prior to 1988 and after 1988 and that male patients with a large spleen size did poorly. Table 11 shows the summary table for presentation of these data. Here we see that soon after diagnosis the chemotherapy patients do better, but among long-term survivors the BMT patients do better.
While Table 10 tells the story in terms of the rate of death, this table fails to answer the key question 'for a given patient with a certain set of covariates, at what times are these two treatments different?' This is particularly important when one treatment has a higher early survival but a lower long-term survival as we have here. We suggest plotting the predicted survival functions of two treatments for a given set value of risk factors, and comparing the difference between the survival functions along with a confidence band for the difference. Visually examining these plots and comparing the confidence bands with the zero line shows how the difference between the two survival functions changes over time. Also the time region where two survival functions are different can be identified from the plot, ie the time region where zero lies outside the 95% confidence bands. Zhang and Klein 17 provide detailed procedures to construct such confidence bands. Bone Marrow Transplantation and after 1988 for male patients with small spleen sizes. In male patients with small spleen sizes diagnosed prior to 1988 we see that the there was a survival advantage up to about 36 months (the upper confidence band is below the 0 line until this point), between about 36-90 months there is no advantage to either treatment (the band includes the zero line) and after 90 months the survival probabilities are higher for a BMT patient. For more recently treated patients it appears, except for a short window around 14-16 months, the survival rates are similar for the two treatments and after 60 months there is a clear advantage for BMT.
Cox model A model which relates covariates or risk factors to outcome. The model, first proposed by Sir David Cox, 4 assumes that the hazard rate for an individual with a set of covariates is the product of a baseline hazard rate and a parametric function of the risk factors.
Disease-free survival The chance a patient is alive and disease-free at a given point in time after transplant.
Factor Something which effects outcome. A factor, as opposed to a covariate, is a set of variables that represent a disease or patient characteristic. For example, donor type, which has five categories in our example, is a factor that is expressed as four binary covariates.
Fixed time covariates
Covariates or risk factors whose values are known at the start of the study and whose values do not change during the course of the study. Examples are pretransplant risk factors, gender, age at diagnosis, etc.
Hazard rate The rate at which an event is occurring. The hazard rate of death is approximately the chance of dying in the next moment in time among current survivors. The hazard rate is the slope of the negative of the natural log of the survival function.
Imputation A body of techniques for missing values where the missing value is replaced (imputed) by an estimated value. The estimated values are based on the value of this covariate in similar patients who have this covariate recorded.
Interaction One variable has a different effect on the outcome depending upon the value of another variable. That is, there is an interaction between two variables if a change in one variable produces a change in outcome at one level of the second variable different from that produced at other levels of the second variable. Testing of an interaction is done by including both variables in the model, as well as their cross-product (A × B) and testing the significance of the cross-product term.
Matched pairs analysis Techniques where each patient on one treatment arm (called a case) is matched to one or more patients on a different treatment arm (controls). The matching is on the basis of commonly known important prognostic factors. Special statistical methods which account for this matching are needed to analyze this type of data. This design is most commonly used in epidemiology to determine if some factor is associated with disease by matching patients with the disease (cases) with healthy patients (controls) on all factors but the one of interest.
Multiple degree of freedom test A hypothesis test for the comparison of three or more treatments or for factors with three or more levels. A multiple degree of freedom test of the hypothesis of no difference in donor types in our example is a test of the hypothesis that all donor types have the same outcome as opposed to the hypotheses that at least one of the donor types has a different outcome from the others. Nonparametric procedure A statistical method which makes no assumptions about a model for the data. Nonparametric tests are also known as distribution-free tests. Two sample nonparametric tests tend to compare the complete distribution of the data in each sample not some measure of the distribution in each sample. In the complete data setting these are typically tests based on ranks and simple counts.
Outliers Values for a variable that deviate appreciably from most other values of that variable in the data set. P value The probability of seeing a more extreme result than observed, if the model is correct. This also known as the observed significance level. Parametric procedures These are procedures which assume that the data come from a family of statistical distributions indexed by some parameter. They require an assumption of a model for the data with some unknown parameter. Tests are about some summary population measure (a parameter) like the mean or variance. Typical examples are the analysis of variance or the t-test for uncensored data which assumes that data is from a normal distribution. These tests can be misleading if the assumed model is wrong, but they are usually more powerful when the model is correct.
Proportional hazards model See Cox model.
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Regression analysis Techniques which are used to study prognostic factors or to adjust for treatment imbalances when comparing treatments. These techniques involve a model that relates covariates to outcome.
Risk set
The collection of all subjects who could experience an event at time t. Semiparametric model A model or procedure where the data are modelled by a combination of an arbitrary function and a specific parametric model. The Cox model is a semiparametric model since we model the hazard rate for an individual by a general baseline function (the nonparametric part) times a specific parametric function of the covariates.
Standard deviation
The square root of the variance. It is a measure of dispersion.
Standard error
The standard deviation of an estimator. It is a measure of the precision of an estimator.
Survival function
The chance a patient is alive at time t.
Time-dependent covariates Prognostic or risk factors whose value changes over time. Examples would be weekly white blood counts, occurrence of GVHD, etc.
Time-varying fixed effects Artificial time-dependent covariates which represent the effect in different time periods of a covariate whose value is unchanging over time. These are typically adjustments for nonproportional hazards.
